Shanxi Zhendong Pharmaceutical Co.,Ltd

300158

CNE100000YR9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-07-14 pm EDT			5-day change	1st Jan Change
3.88 ^CNY	-1.77%		+0.78%	-42.52%

May. 20	Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Board Appointments	CI
May. 06	Tranche Update on Shanxi Zhendong Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on February 6, 2024.	CI

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Directorate Appointments

May 25, 2020 at 03:35 pm EDT

Shanxi Zhendong Pharmaceutical Co.,Ltd at its AGM held on May 22, 2020 approved appointment of Ma Shifeng and Miao Hui as a director.

Latest news about Shanxi Zhendong Pharmaceutical Co.,Ltd

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Board Appointments	May. 20	CI
Tranche Update on Shanxi Zhendong Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on February 6, 2024.	May. 06	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd's Equity Buyback announced on February 6, 2024, has closed with 22,174,904 shares, representing 2.16% for CNY 102.76 million.	Apr. 29	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 22	CI
Tranche Update on Shanxi Zhendong Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on February 6, 2024.	Apr. 03	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd agreed to acquire additional 53.985% stake in Guangdong Longchuangji Pharmaceutical Co., Ltd. from Guangdong Qiangji Pharmaceutical Co., Ltd.	Mar. 07	CI
Guangdong Longchuangji Pharmaceutical Co., Ltd. announced that it has received CNY 30 million in funding from Shanxi Zhendong Pharmaceutical Co.,Ltd	Mar. 06	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd announces an Equity Buyback for CNY 200 million worth of its shares.	Feb. 06	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd authorizes a Buyback Plan.	Feb. 05	CI
Guangdong Longchuangji Pharmaceutical Co., Ltd. announced that it expects to receive CNY 30 million in funding from Shanxi Zhendong Pharmaceutical Co.,Ltd	Jan. 18	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-22	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-24	CI
FountainVest Capital Partners Fund IV, L.P., a fund managed by Fountain Vest Capital Partners GP4 Ltd. completed the aquistion of Beijing Zhendong Langdi Pharmaceutical Co., Ltd. from Shanxi Zhendong Pharmaceutical Co.,Ltd.	22-10-27	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd(XSEC:300158) added to S&P Global BMI Index	22-09-19	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-21	CI
Zhongtai Asset Management Plan No. 45 Single Asset Management Plan, managed by Zhongtai Securities Asset Management Co.,Ltd. completed the acquisition of a 5% stake in Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE : 300158) from Shanxi Zhendong Health Industry Group Co., Ltd.	22-07-14	CI
Zhongtai Asset Management Plan No. 45 Single Asset Management Plan, managed by Zhongtai Securities Asset Management Co.,Ltd. signed a share transfer agreement to acquire a 5% stake in Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE : 300158) from Shanxi Zhendong Health Industry Group Co., Ltd. for approximately CNY 340 million.	22-06-19	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on 09 May 2022	22-04-26	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Approves 2021 Profit Distribution Plan	22-04-25	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-21	CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Proposes Final Cash Dividend for 2021	22-03-31	CI

Chart Shanxi Zhendong Pharmaceutical Co.,Ltd

Duration

Period

Chart Shanxi Zhendong Pharmaceutical Co.,Ltd

More charts

Shanxi Zhendong Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, production and sale of Chinese patent drugs, chemical raw materials and preparations. The Company's main products include anti-tumor series, cardiovascular and cerebrovascular series, anti-infection series, digestive system series, vitamin nutrition series, respiratory system series, antipyretic analgesic series and nervous system series. The Company is also involved in the cultivation of medicinal herbs, as well as the wholesale and retail of pharmaceutical products. The Company distributes its products in domestic market, with North China market as its main market.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHANXI ZHENDONG PHARMACEUTICAL CO.,LTD	-42.52%	550M
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+39.05%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+13.66%	244B
ROCHE HOLDING AG	+5.44%	234B
NOVARTIS AG	+16.58%	226B
AMGEN INC.	+14.63%	177B

Other Pharmaceuticals